Cargando…

Disease-modifying treatments in Alzheimer’s disease

Detalles Bibliográficos
Autores principales:	Edwards, Marc, Corkill, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Journal Club
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933805/ https://www.ncbi.nlm.nih.gov/pubmed/36795148 http://dx.doi.org/10.1007/s00415-023-11602-8

Ejemplares similares

Seizures in Alzheimer’s disease: is there more beneath the surface?
por: Edwards, Marc, et al.
Publicado: (2017)

Treatments in Alzheimer’s disease
por: Malik, G. A., et al.
Publicado: (2017)

New treatments in Alzheimer’s disease
por: Pickrell, William O., et al.
Publicado: (2018)

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
por: McArthur, C., et al.
Publicado: (2023)

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies
por: Hrastelj, James, et al.
Publicado: (2017)

Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders
por: Peall, K. J., et al.
Publicado: (2016)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

Stem cells in the treatment of central nervous system disease
por: McLauchlan, Duncan, et al.
Publicado: (2018)

Parkinson, Alzheimer und MS in Coronazeiten
por: Wietelmann, Detlef
Publicado: (2021)

Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia
por: Saw, Aung M., et al.
Publicado: (2023)

What Is the Profiles for Predicting Treatment Responsiveness in Gastroesophageal Reflux Disease? (Gut 2012;61:501-506)
por: Park, Seon Young
Publicado: (2012)

Socioeconomic status in neurological disorders: a modifiable risk factor?
por: Hrastelj, J., et al.
Publicado: (2022)

Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease
por: Willis, M. D., et al.
Publicado: (2018)

Pathological looping in the synucleinopathies: investigating the link between Parkinson’s disease and Gaucher disease
por: Kinghorn, Kerri J.
Publicado: (2011)

Sleep disorders in Parkinson’s disease
por: Hawken, Jonathan, et al.
Publicado: (2022)

Obesity and Functional Gastrointestinal Diseases in Children: (Int J Obes [Lond] Published Online First: 2 May 2014. doi: 10.1038/ijo.2014.67)
por: Rajindrajith, Shaman, et al.
Publicado: (2014)

The economic burden of chronic neurological disease
por: Wynford-Thomas, R., et al.
Publicado: (2017)

Repurposing drugs to treat neurological diseases
por: Massey, T. H., et al.
Publicado: (2018)

The gut microbiome: neurological development and disease
por: Miah, Latif, et al.
Publicado: (2022)

New ways of looking at an old disease: the reimagination of epilepsy
por: Mitchell, Clinton J., et al.
Publicado: (2016)

Creutzfeldt–Jacob disease: new directions in diagnosis and therapeutics
por: Al-Ansari, Aseel, et al.
Publicado: (2017)

A NOD to zebrafish models of inflammatory bowel disease pathogenesis
por: Allen, Irving C.
Publicado: (2011)

Multiple sclerosis: early indicators of disease and assessing future risk
por: Willis, M. D., et al.
Publicado: (2020)

Understanding gene-environment interactions in a mouse model of Crohn’s disease
por: Duckworth, Carrie A.
Publicado: (2011)

Intracerebral haemorrhage on the acute stroke unit
por: Edwards, M. D., et al.
Publicado: (2019)

Parkin’ control: regulation of PGC-1α through PARIS in Parkinson’s disease
por: Castillo-Quan, Jorge Iván
Publicado: (2011)

Maple syrup urine disease: new insights from a zebrafish model
por: Roberts, Nathan B.
Publicado: (2012)

Data Speak How to Treat Disease: Big data-based precision medicine
por: Hwang, Daehee
Publicado: (2022)

Psychosocial factors and their influence on the experience of pain: response to commentary
por: Edwards, Rhiannon, et al.
Publicado: (2017)

The exposome in respiratory diseases: multiple preventable risk factors from early life to adulthood
por: Savouré, Marine, et al.
Publicado: (2023)

The role of skin biopsy in differentiating idiopathic Parkinson’s disease from other types of parkinsonism
por: Wynford-Thomas, Ray, et al.
Publicado: (2015)

Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis–Related Interstitial Lung Disease
por: Tiwari, Vivekanand, et al.
Publicado: (2021)

Does 22q11.2 deletion syndrome contribute to the genetic aetiology of Parkinson’s disease?
por: Fung, W., et al.
Publicado: (2018)

Anteil an Geimpften in der Bevölkerung und Coronavirus Disease 2019(COVID‑19)-Fälle – Limitationen und irreführende Schlussfolgerungen
por: Umlauf, Julian, et al.
Publicado: (2022)

Cellular Senescence: The Villain of Metabolic Disease?: Discovery of a distinct senescent cell population in obesity-induced metabolic dysfunction
por: Lee, Gung
Publicado: (2022)

Arbaclofen Placarbil Decreases Reflux With Good Tolerability in Patients With Gastroesophageal Reflux Disease (Am J Gastroenterol 2010;105:1266-1275)
por: Kim, Gwang Ha
Publicado: (2010)

Columnar-lined Esophagus: Its Prevalence and Predictors in Patients With Gastroesophageal Reflux Disease (Am J Gastroenterol 2012;107:1655-1661)
por: Kim, Gwang Ha
Publicado: (2013)

An update on treatments in myasthenia gravis
por: Jones, Lliwen A., et al.
Publicado: (2016)

Cannabidiol as a treatment for epilepsy
por: Pickrell, William O., et al.
Publicado: (2017)

Treatment of progressive multifocal leukoencephalopathy
por: Castle, Daniel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_luk5q3ja7fr74k6ov699os4ntr